Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Merck & Co Inc MRK

Healthcare
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for... see more

Recent & Breaking News (NYSE:MRK)

Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions

Livemoney August 25, 2020

Merck's KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan

Business Wire August 24, 2020

Merck's KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer

Business Wire August 19, 2020

QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma

ACN Newswire August 13, 2020

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020

GlobeNewswire August 11, 2020

Merck Animal Health Completes Acquisition of IdentiGEN

Business Wire August 5, 2020

Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Efinopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)

Business Wire August 4, 2020

Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio

Business Wire August 3, 2020

Merck Announces Second-Quarter 2020 Financial Results

Business Wire July 31, 2020

Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)

Business Wire July 30, 2020

FDA Grants Breakthrough Therapy Designation to Merck's Novel HIF-2? Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma

Business Wire July 29, 2020

Merck Announces Fourth-Quarter 2020 Dividend

Business Wire July 28, 2020

New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight

Livemoney July 21, 2020

FDA Grants Priority Review to Merck's New Drug Application for Vericiguat

Business Wire July 16, 2020

Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews

Business Wire July 9, 2020

FDA Grants Priority Review to Merck's Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Business Wire July 9, 2020

Merck Announces Appointment of Organon & Co. General Counsel

Business Wire July 8, 2020

LYNPARZA® (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer

Business Wire July 8, 2020

Merck and Eisai Receive Complete Response Letter for KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Business Wire July 8, 2020

Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection

Business Wire July 6, 2020